Skip to main content

Diagnosis of Systemic Lupus Erythematosus in the Age of Precision Medicine

  • Chapter
  • First Online:
Diagnoses Without Names
  • 355 Accesses

Abstract

Most autoimmune inflammatory rheumatologic disorders are multisystem and heterogeneous with several shared features, especially at the early stages. Early diagnosis is usually difficult, as physicians have to discriminate from non-rheumatic disorders as well as among autoimmune diseases with overlapping manifestations. Moreover, the serum markers are shared across these diseases, such as an anti-nuclear antibody or rheumatoid factor, that contribute to making a diagnosis uncertain at times. When there is no gold standard in support of diagnosis or classification, a substantial group of patients remains undiagnosed for years. Precision or personalized medicine, a concept that has been pioneered in oncology, posits that that individual genetic risk and molecular pathogenesis can contribute to accurate diagnosis and offer the most appropriate therapy options for a given patient. Recent advances in technology and analytical tools that assess big data now present the possibility of more accurate classification of diseases and pave the way to precision medicine in rheumatology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ludmerer KM. Commentary: understanding the Flexner report. Acad Med. 2010;85(2):193–6.

    Article  PubMed  Google Scholar 

  2. Duffy TP. The Flexner report–100 years later. Yale J Biol Med. 2011;84(3):269–76.

    PubMed  PubMed Central  Google Scholar 

  3. Shai R, Quismorio FP, Li L, Kwon OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet. 1999;8(4):639–44.

    Article  CAS  PubMed  Google Scholar 

  4. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, et al. Familial aggregation of systemic lupus erythematosus and Coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015;175(9):1518–26.

    Article  PubMed  Google Scholar 

  5. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35(3):311–8.

    Article  CAS  PubMed  Google Scholar 

  6. Catalina MD, Bachali P, Yeo AE, Geraci NS, Petri MA, Grammer AC, et al. Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight. 2020;5(15).

    Google Scholar 

  7. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753–63.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009;36(6):1200–8.

    Article  PubMed  Google Scholar 

  9. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore). 2004;83(1):1–17.

    Article  Google Scholar 

  10. Morgan C, Bland AR, Maker C, Dunnage J, Bruce IN. Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus. 2018;27(4):681–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    Article  CAS  PubMed  Google Scholar 

  12. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018;70(3):428–38.

    Article  CAS  Google Scholar 

  14. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res (Hoboken). 2019;71(7):893–902.

    Article  CAS  Google Scholar 

  15. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v4–v11.

    Article  CAS  Google Scholar 

  17. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Acosta-Mérida A, Isenberg DA. Antinuclear antibodies seroconversion in 100 patients with lupus. Clin Exp Rheumatol. 2013;31(4):656.

    PubMed  Google Scholar 

  20. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Putterman C, Pisetsky DS, Petri M, Caricchio R, Wu AHB, Sanz I, et al. The SLE-key test serological signature: new insights into the course of lupus. Rheumatology (Oxford). 2018;57(9):1632–40.

    Article  CAS  Google Scholar 

  22. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.

    Article  CAS  PubMed  Google Scholar 

  23. Pisetsky DS, Spencer DM, Rovin B, Lipsky PE. Role of ANA testing in the classification of patients with systemic lupus erythematosus. Ann Rheum Dis. 2019; https://doi.org/10.1136/annrheumdis-2019-216259.

  24. Aggarwal A. Role of autoantibody testing. Best Pract Res Clin Rheumatol. 2014;28(6):907–20.

    Article  PubMed  Google Scholar 

  25. Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med. 2014;1(1):e000056.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Vasquez-Canizares N, Wahezi D, Putterman C. Diagnostic and prognostic tests in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):351–63.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Giannopoulou EG, Elemento O, Ivashkiv LB. Use of RNA sequencing to evaluate rheumatic disease patients. Arthritis Res Ther. 2015;17:167.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011;7(2):e1001311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–30.

    Article  CAS  PubMed  Google Scholar 

  31. Brown MA, Aletaha D. Genetic risk scores in inflammatory arthritis: a new era? Nat Rev Rheumatol. 2020;16(10):545–6.

    Article  PubMed  Google Scholar 

  32. Chen L, Wang YF, Liu L, Bielowka A, Ahmed R, Zhang H, et al. Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity. Hum Mol Genet. 2020;29(10):1745–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Webb R, Kelly JA, Somers EC, Hughes T, Kaufman KM, Sanchez E, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2011;70(1):151–6.

    Article  PubMed  Google Scholar 

  34. Gianfrancesco MA, Balzer L, Taylor KE, Trupin L, Nititham J, Seldin MF, et al. Genetic risk and longitudinal disease activity in systemic lupus erythematosus using targeted maximum likelihood estimation. Genes Immun. 2016;17(6):358–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Reid S, Alexsson A, Frodlund M, Morris D, Sandling JK, Bolin K, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Ann Rheum Dis. 2020;79(3):363–9.

    Article  CAS  PubMed  Google Scholar 

  36. Oglesby A, Korves C, Laliberté F, Dennis G, Rao S, Suthoff ED, et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy. 2014;12(2):179–90.

    Article  PubMed  Google Scholar 

  37. Knevel R, le Cessie S, Terao CC, Slowikowski K, Cui J, Huizinga TWJ, et al. Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. Sci Transl Med. 2020;12(545).

    Google Scholar 

  38. Haynes WA, Haddon DJ, Diep VK, Khatri A, Bongen E, Yiu G, et al. Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus. JCI Insight. 2020;5(4).

    Google Scholar 

  39. Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23(2):113–21.

    Article  PubMed  CAS  Google Scholar 

  40. Catalina MD, Bachali P, Geraci NS, Grammer AC, Lipsky PE. Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. Commun Biol. 2019;2:140.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014–21.

    Article  CAS  PubMed  Google Scholar 

  42. Jackson SW, Jacobs HM, Arkatkar T, Dam EM, Scharping NE, Kolhatkar NS, et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213(5):733–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1):150–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Flint SM, Jovanovic V, Teo BW, Mak A, Thumboo J, McKinney EF, et al. Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open. 2016;2(1):e000183.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Alarcón-Riquelme ME. New attempts to define and clarify lupus. Curr Rheumatol Rep. 2019;21(4):11.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013;43:78–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized Immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(6):1548–50.

    Article  CAS  PubMed  Google Scholar 

  48. Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, et al. Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS One. 2018;13(12):e0208132.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus. 2009;18(1):78–80.

    Article  CAS  PubMed  Google Scholar 

  50. Sladkova V, Mares J, Lubenova B, Hlustik P, Kanovsky P. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett. 2011;32(1):4–6.

    PubMed  Google Scholar 

  51. Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol. 2019;

    Google Scholar 

  52. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483–95.

    Article  PubMed  Google Scholar 

  53. Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20(7):915–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, et al. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight. 2017;2(9).

    Google Scholar 

  55. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1771–4.

    Article  PubMed  Google Scholar 

  56. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55(6):864–72.

    Article  PubMed  Google Scholar 

  57. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol. 2002;169(1):5–9.

    Article  CAS  PubMed  Google Scholar 

  58. Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63(11):1387–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hubbard EL, Catalina MD, Heuer S, Bachali P, Robl R, Geraci NS, et al. Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis. Sci Rep. 2020;10(1):17361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yavuz, S., Lipsky, P.E. (2022). Diagnosis of Systemic Lupus Erythematosus in the Age of Precision Medicine. In: Lockshin, M.D., Crow, M.K., Barbhaiya, M. (eds) Diagnoses Without Names. Springer, Cham. https://doi.org/10.1007/978-3-031-04935-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04935-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04934-7

  • Online ISBN: 978-3-031-04935-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics